

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Vexler Vladimir</u> (Last) (First) (Middle) <u>COHERUS BIOSCIENCES, INC.</u> <u>333 TWIN DOLPHIN DRIVE, SUITE 600</u> (Street) <u>REDWOOD CITY CA 94065</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>11/16/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc. [CHRS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Scientific Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) <u>11/20/2018</u> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock, \$0.0001 par value</u>	<u>10,800⁽¹⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Stock Option (right to buy)</u>	<u>(2)</u>	<u>02/28/2023</u>	<u>Common Stock</u>	<u>71,982</u>	<u>2.0838</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(3)</u>	<u>04/01/2025</u>	<u>Common Stock</u>	<u>25,000</u>	<u>29</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(4)</u>	<u>02/26/2026</u>	<u>Common Stock</u>	<u>25,000</u>	<u>14.43</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(5)</u>	<u>05/11/2026</u>	<u>Common Stock</u>	<u>24,618</u>	<u>17.17</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>04/03/2027</u>	<u>Common Stock</u>	<u>25,000</u>	<u>20.15</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(7)</u>	<u>08/06/2027</u>	<u>Common Stock</u>	<u>50,000</u>	<u>12.7</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(8)</u>	<u>11/15/2027</u>	<u>Common Stock</u>	<u>25,000</u>	<u>9.3</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(9)</u>	<u>02/01/2028</u>	<u>Common Stock</u>	<u>75,000</u>	<u>10.05</u>	<u>D</u>

Explanation of Responses:

- This Form 3 amendment has been filed solely to correct the amount of securities beneficially owned as shown in Table I, column 2.
- The original grant was for 86,982 shares, of which 15,000 shares have been exercised and sold. The remaining shares underlying this option are fully vested and exercisable as of the date hereof.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 1, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 1, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 6, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable over two years as follows: Fifty percent (50%) of the underlying shares subject to the option vest and become exercisable on August 1, 2018, an additional twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on February 1, 2019 and twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on August 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

/s/ Jean-Frederic Viret, as
Attorney-in-Fact for Vladimir Vexler 01/14/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.